Anticuerpos monoclonales antiangiogénicos
Ruff et al. Eur J Cancer 2015, Tabernero J Clin Oncol 2012, Salgado. Monografía Thrombosis Risk 2015
Bevacizumab – aflibercept (AF) – ramucirumab (RAM)
Not appear to be associated to a significant
increase in the risk of VTE
Increase VTE with some chemo combinations
(platinum compounds, gemcitabine)
Bv is associated to a modest, but significant
increase in the risk of arterial TED of approximately
2-3%
–
A prior arterial thromboembolic event (p<0.001)
–
Age of 65 years or older (p=0.01)
AF&RAM probably associated to arterial TED
